Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer

NCT02202746 is registered in ClinicalTrials.gov with Clovis Oncology, Inc. as lead sponsor.

NCT NCT02202746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02202746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer
Lead sponsor
Clovis Oncology, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
September 9, 2014
Completion date
January 18, 2017
Enrollment
178 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, er, estrogen receptor positive, her2, her2 positive, mbc, metastatic breast cancer, triple negative